This page shows the latest Ultomiris news and features for those working in and with pharma, biotech and healthcare.
NICE said clinical evidence shows Ultomiris is as effective and safe as Alexion's older PNH drug Soliris. ... Compared with Alexion’s older drug, Ultomiris is a cost-effective use of NHS resources, concluded NICE.
Alexion’s other long-acting C5 inhibitor, Ultomiris (ravulizumab‑cwvz) is also approved in these indications, making the franchise Novartis potential main competitors.
This includes the company’s complement component 5 (C5) inhibitors Soliris (eculizumab) and Ultomiris (ravulizumab), which are already available in the US and EU.
with C5 inhibitor Soliris and Alexion’s follow-up Ultomiris (ravulizumab), which brought in $990m and $90m respectively in the third quarter of 2019. ... Alexion was quick to point out that the standard treatment for PNH is shifting from Soliris to
Both Achillion’s drugs could be used in combination with Soliris as well as Alexion’s longer-acting follow-up drug Ultomiris (ravulizumab) in PNH – a life-threatening disorder in which
PNH therapy Ultomiris (ravulizumab), which was granted an earlier than expected FDA approval last December. ... In trials, Ultomiris matched Soliris for efficacy – with a trend towards superiority – and offers improved dosing.
More from news
Approximately 1 fully matching, plus 8 partially matching documents found.
The forecast for 2023 sales is $1.97bn. Ultomiris (ravulizumab), from Alexion, treats paroxysmal nocturnal haemoglobinuria, a rare, potentially fatal blood disorder. ... Ultomiris received approval as an Orphan Drug from the FDA for adult patients with
Analysts predict peak sales of up to $3bn. 5. Ultomiris – Alexion’s follow-up to Soliris. ... The follow-up, Ultomiris ALXN1210, is a second-generation PNH therapy with an NPV of $10.9bn.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...